Identification of F5 as a Prognostic Biomarker in Patients with Gastric Cancer

Table 4

The prognostic value of the mRNA expression of F5 in various clinical features GC patients from KM-plotter.

Group	Low	High	HR (95% CI)	value
All	177	171	1.43 (1.1−1.88)	0.0085
Histology
Intestinal	65	63	1.47 (0.92−2.35)	0.11
Diffuse	52	53	1.07 (0.65−1.76)	0.78
Mixed	11	11	1.84 (0.45−7.44)	0.39
TNM stage
Stage I	17	17	1.58 (0.44−5.66)	0.48
Stage II	22	22	0.99 (0.39−2.5)	0.98
Stage III	54	55	1.78 (1.1−2.87)	0.017
Stage IV	34	32	1.33 (0.74−2.42)	0.34
HER2 status
Negative	99	96	1.31 (0.92−1.87)	0.14
Positive	78	75	1.42 (0.94−2.14)	0.096
Differentiation
Poorly	60	61	1.41 (0.87−2.3)	0.17
Moderately	34	33	1.83 (0.93−3.58)	0.074
Well	2	3
5-Fu treatment	17	17	1.32 (0.53–3.29)	0.55

Abbreviations: F5—Coagulation factor V; HR—hazard ratio; OS—overall survival; GC—gastric cancer, T—tumour; N—node; M—metastasis.